

Anti-ICOS/CD278 Antibody (Vopratelimab)

Introduction

Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that specifically binds to inducible T-cell CO stimulator (ICOS). Vopratelimab retains species cross-reactivity with an affinity of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. Vopratelimab has an anti-tumor immune response.

Product parameters

Alternative Names	JTX-2011, vopra
Target Accession	Q9Y6W8
Target	ICOS / CD278
CAS number	2039148-04-2
Molecular Weight	145.8 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

